Journal article
Engineering cells with intracellular agent-loaded microparticles to control cell phenotype
Nature protocols, Vol.9(2), pp.233-245
02/2014
DOI: 10.1038/nprot.2014.002
PMCID: PMC4320648
PMID: 24407352
Abstract
Cell therapies enable unprecedented treatment options to replace tissues, destroy tumors and facilitate regeneration. The greatest challenge facing cell therapy is the inability to control the fate and function of cells after transplantation. We have developed an approach to control cell phenotype in vitro and after transplantation by engineering cells with intracellular depots that continuously release phenotype-altering agents for days to weeks. The platform enables control of cells' secretome, viability, proliferation and differentiation, and the platform can be used to deliver drugs or other factors (e.g., dexamethasone, rhodamine and iron oxide) to the cell's microenvironment. The preparation, efficient internalization and intracellular stabilization of ∼1-μm drug-loaded microparticles are critical for establishing sustained control of cell phenotype. Herein we provide a protocol to generate and characterize micrometer-sized agent-doped poly(lactic-co-glycolic) acid (PLGA) particles by using a single-emulsion evaporation technique (7 h), to uniformly engineer cultured cells (15 h), to confirm particle internalization and to troubleshoot commonly experienced obstacles.
Details
- Title: Subtitle
- Engineering cells with intracellular agent-loaded microparticles to control cell phenotype
- Creators
- James A Ankrum - 1] Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Harvard-MIT Division of Health Sciences and Technology, Harvard Stem Cell Institute, Cambridge, Massachusetts, USAOscar R Miranda - 1] Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Harvard-MIT Division of Health Sciences and Technology, Harvard Stem Cell Institute, Cambridge, Massachusetts, USAKelvin S Ng - 1] Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Harvard-MIT Division of Health Sciences and Technology, Harvard Stem Cell Institute, Cambridge, Massachusetts, USADebanjan Sarkar - Department of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, New York, USAChenjie Xu - Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, SingaporeJeffrey M Karp - 1] Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Harvard-MIT Division of Health Sciences and Technology, Harvard Stem Cell Institute, Cambridge, Massachusetts, USA
- Resource Type
- Journal article
- Publication Details
- Nature protocols, Vol.9(2), pp.233-245
- DOI
- 10.1038/nprot.2014.002
- PMID
- 24407352
- PMCID
- PMC4320648
- NLM abbreviation
- Nat Protoc
- ISSN
- 1750-2799
- eISSN
- 1750-2799
- Publisher
- England
- Grant note
- R01 HL095722 / NHLBI NIH HHS HL095722 / NHLBI NIH HHS
- Language
- English
- Date published
- 02/2014
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering
- Record Identifier
- 9984001077702771
Metrics
32 Record Views